Table 1.

Responses to olaparib (composite trial endpoint and per each of the components) based on the origin and type of the qualifying genomic alterations

	All patients, by type of response										Composite overall response by gene subgroup
	Composite overall response		RECIST 1.1 objective response		PSA fall ≥50%		CTC conversion		RECIST 1.1 or PSA response		BRCA1/2		PALB2		ATM		CDK12
	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR	Resp/n	RR
All randomized patients	45/98	45.9	14/75	18.7	31/95	32.6	29/57	50.9	33/98	33.7	26/32	81.3	4/7	57.1	8/21	38.1	5/21	23.8
By origin/type alteration
Germline mutation	19/30	63.3	6/22	27.3	12/28	42.9	11/19	57.9	13/30	43.3	10/13	76.9	4/6	66.7	4/5	80	1/1	100
Somatic homozygous deletion	10/16	62.5	4/11	36.4	10/16	62.5	7/11	63.6	10/16	62.5	9/11	81.8	0/0	0	1/1	100	0	0
Somatic mutation	16/52	30.8	4/42	9.5	9/51	17.6	11/27	40.7	10/52	19.2	7/8	87.5	0/1	0	3/15	20	4/20	20
Based on the evidence of biallelic loss
Biallelic hit detected	33/64	51.6	10/47	21.3	24/64	37.5	22/39	56.4	25/64	39.1	19/24	79.2	4/4	100	5/12	41.7	4/18	22.2
Monoallelic hit detected	12/34	35.3	4/28	14.3	7/31	22.6	7/18	38.9	8/34	23.5	7/8	87.5	0/3	0	3/9	33.3	1/3	33.3

Abbreviations: n, patients available; Resp, number of responses; RR, response rate (%).